Omnicell (NASDAQ:OMCL) Updates Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.150-0.250 for the period, compared to the consensus EPS estimate of 0.310. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $264.9 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Trading Up 1.9 %

NASDAQ OMCL traded up $0.73 on Friday, hitting $40.16. The company's stock had a trading volume of 797,215 shares, compared to its average volume of 344,813. The firm has a market cap of $1.86 billion, a P/E ratio of 148.75, a PEG ratio of 26.98 and a beta of 0.78. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The company's 50-day simple moving average is $44.21 and its 200 day simple moving average is $43.38. The company has a current ratio of 1.37, a quick ratio of 0.95 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Research analysts predict that Omnicell will post 1.04 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on OMCL shares. StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. Barclays upped their price target on Omnicell from $39.00 to $58.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. raised their price objective on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research report on Thursday, November 21st. Finally, Craig Hallum upped their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $52.33.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.64% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.